Deletions of the 3'BCR and 5'ABL regions in patients with Philadelphia-positive chronic myeloid leukemia: a one-step process occurring in about 10% of the cases without any evidence of genetic instability in the target cells.
Deletions of the 5'ABL region adjacent to the t(9;22)(q34;q11) have recently been reported in 8-32.7% of patients with chronic myeloid leukemia (CML). The deletions were visualized with fluorescence in situ hybridization using, in the majority of the cases, the Vysis LSI BCR/ABL ES (extra signal) probe. In our series, 10 of 99 CML patients (10.1%) were characterized by a 5'ABL deletion. We show that 3'BCR losses are observed in nearly all the cases with 5'ABL deletions. Moreover, the different genetic events (Philadelphia chromosome formation; 5'ABL and 3'BCR deletions) occur simultaneously in a one-step process without any evidence for genetic instability in the target bone marrow cells.
Center for Human Genetics, University of Liège, CHU, Tour de Pathologie, B23, Sart Tilman, 4000 Liège, Belgium.
Mickaël
M
Fournier
Stéphanie
S
Lacrosse
Mauricette
M
Jamar
Vincent
V
Bours
Christian
C
Herens
D005260:Female; D016044:Fusion Proteins, bcr-abl / Q000235:genetics*; D042822:Genomic Instability / Q000235:genetics*; D006801:Humans; D017404:In Situ Hybridization, Fluorescence; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000235:genetics*; D008297:Male; D008875:Middle Aged; D017384:Sequence Deletion / Q000235:genetics*
D016044:Fusion Proteins, bcr-abl